CA
NZ
UK
AU
IND
US
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) is among the smallest US-listed rare-disease biotechs, and it has spent three months stacking up regulatory milestones at a pace few micro-caps manage. The Israeli-incorporated group, run from Ashburn, Virginia, trades through American Depositary Shares representing 35 ordinary shares each.
SeaStar Medical Holding Corporation (NASDAQ:ICU) is trying to prove a product with clinical traction can outrun a shrinking bank balance. The Denver-based company sells QUELIMMUNE, a blood-filtering cartridge approved by the FDA in February 2024 under a Humanitarian Device Exemption, a pathway reserved for …
Sunshine Biopharma, Inc. (NASDAQ:SBFM) filed its second-quarter report on 13 August 2026, and it lands at an awkward moment for a company that spent the summer stacking up regulatory wins. The commercial engine, Canadian generics subsidiary Nora Pharma Inc., is still turning out roughly …
Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) spent early 2026 reporting encouraging cancer data, then agreed to sell the programme that produced it. Its lead candidate, SENTI-202, is an off-the-shelf CAR-NK cell therapy for relapsed or refractory acute myeloid leukaemia (AML), built on engineered genetic circuits …
Few micro-cap medical device companies have had a busier summer than Intelligent Bio Solutions Inc. (NASDAQ:INBS). Since late July the New York-based company has ticked off, one by one, the studies it needs before its first substantive US Food and Drug Administration filing.
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) is one of the smallest clinical-stage eye-disease companies on the exchange, yet it runs two Phase 2 retinal trials while spending remarkably little of its own money.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a micro-cap, clinical-stage biotechnology company that has spent 2026 turning a small skin-cancer study into a real development programme. In eight weeks it has begun commercial-scale manufacturing of its lead drug, reported second-quarter results, added a dermatologist to its …
Akari Therapeutics Plc (NASDAQ:AKTX) has spent 2026 rebuilding itself around one idea: a cancer-drug payload that attacks tumours by jamming the machinery cells use to edit their own genetic instructions.
BioCardia, Inc. (NASDAQ:BCDA) has done something small-cap cell therapy developers rarely manage: turned years of clinical work into a dated regulatory filing. The company is preparing a marketing application in Japan for CardiAMP, its autologous cell therapy for ischemic heart failure, in the fourth …
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) spent years building a case for nebokitug, its experimental antibody for a rare and untreatable liver disease. In July 2026 it agreed to hand the wheel to someone else.
Please wait processing your request...